NanoVibronix (Nasdaq:NAOV) announced today that it completed the first phase of a randomized controlled trial for its UroShield device. Researchers at the University of Michigan completed the first phase of the trial for UroShield, a portable ultrasonic therapeutic device. UroShield utilizes patented low-intensity surface acoustic wave (SAW) … [Read more...] about NanoVibronix completes pilot study for UroShield device
nanovibronix
NanoVibronix’s UroShield receives positive guidance from UK’s NICE
NanoVibronix today received publication of guidance from National Institute for Health and Care Excellence (NICE) in the U.K. for its UroShield device. England's Department of Health and Social Care's NICE issued guidance suggesting that UroShield has the potential to provide significant patient and healthcare system benefits to prevent … [Read more...] about NanoVibronix’s UroShield receives positive guidance from UK’s NICE
NanoVibronix device gains FDA nod for import to U.S.
NanoVibronix (NSDQ:NAOV) announced that it received FDA enforcement discretion for the U.S. distribution of the UroShield device. According to a news release, the FDA exercised its enforcement discretion, giving Elmsford, N.Y.-based NanoVibronix’s UroShield an intended use code (IUC), clearing the way for the import of the system to the U.S. … [Read more...] about NanoVibronix device gains FDA nod for import to U.S.